From Blockbusters to Niche Medicines

CPhI Worldwide and CPhI Pharma Evolution, part of UBM Live’s Pharmaceutical Portfolio, today released Part II of the CPhI annual industry report, in which expert industry panel members share their views on trends that will drive growth and innovation across the pharmaceutical industry over the coming years and beyond.

The pharmaceutical industry is shifting away from the blockbuster model towards the development of personalized medicines and niche, individualized therapies and associated companion diagnostics, noted Sam Venugopal, director, healthcare, PricewaterhouseCoopers. These drugs target specific populations and genomic makeups and are known to have greater efficacy. William Botha, Sensei at Interlean, added that there will also be companies moving towards commodity-based, low-margin products. As a result, one can expect to see increased specialization, particularly amongst small and medium companies. Read more »

President Obama’s Plans for Healthcare Reform and Job Growth

President Obama’s State of the Union Address on Feb. 12, 2013 touched on some issues that may directly impact the pharmaceutical industry: healthcare reform, innovation, and job creation. So how has the pharmaceutical industry responded?

Read more »

2012 European Outsourcing Award Winners

The 2012 European Outsourcing Awards—what some call the “Outsourcing Oscars”—were presented on October 10, 2012 during the CPhI Worldwide/iCSE show and included awards to Vetter for a high-speed filling line and to Catalent for updates to its controlled-release facility. Read more »

PharmTech Biomanufacturing Partnership Conference: The Rising Bar in Outsourcing

Patricia Van Arnum PharmTech editorWhat will be the future of pharmaceutical outsourcing? What factors will influence the relationships between sponsor companies and contract service providers and what practical solutions are both seeking? These questions were addressed at a conference this week in Philadelphia, Bio/Pharmaceutical Manufacturing Partnerships, organized by CBI in conjunction with Pharmaceutical Technology. Read more »

Live from Intephex 2012: The State of the Outsourcing Industry

Angie DrakulichJim Miller of PharmSource gave a keynote talk this week at Interphex 2012 in New York City on the state of the industry’s outsourcing environment. Miller is also a member of the PharmTech Editorial Advisory Board. Below are a few highlights from his talk. Read more »

Is the US Facing a Pharmaceutical Manufacturing Gap?

Patricia Van Arnum PharmTech editor Last week, FDA Commissioner Margaret A. Hamburg testified before the House Committee on Energy and Commerce, Subcommittee on Health to outline the agency’s case for supporting the fifth authorization of the Prescription Drug User Fee Act (PDUFA), also known as PDUFA V. In addition to offering her support for PDUFA V, Hamburg also discussed renewal of legislation for promoting pediatric drug testing, the need of FDA to invest in science and innovation, and the agency’s efforts in confronting the continual challenges of globalization. In tackling globalization, a basic question arises: does the United States face a pharmaceutical manufacturing disconnect? Read more »

Building Relationships at CPhI

Patricia Van Arnum PharmTech editor In attending CPhI this week in Frankfurt, one theme that repeatedly emerged was the increasing importance of CROs, CDMOs, and CMOs to build more strategic, deeper, and collaborative relationships with pharmaceutical companies as a way to meet the evolving needs of the industry and as a a mutual tool in value creation. Read more »

The UK, Bribery and Pharma

Stephanie Sutton Pharm Tech EuropeBribery and corruption are not supposed to happen, but of course they do happen and no industry is immune. In 2009, the World Health Organisation estimated that healthcare fraud and abuse can cost individual governments as much as $23 billion a year.

Fortunately, there are many rules and watchdog organisation keeping a close eye on businesses to make sure everything is honest and above board. In the UK, bribery rules have recently been strengthened by the long-awaited (or long-dreaded depending on how you look at it) Bribery Act 2010. Although it’s UK legislation, it has a long reach. It will impact any corporate entity that conducts business in the UK and applies to business interactions both inside and outside the UK. Read more »

Big Pharma, We Hardly Knew Ye

Erik Greb PharmTech editorBig Pharma’s sales forecast is not likely to improve anytime soon. Consulting firm Bain and Company predicts that the top 25 drug companies’ annual sales growth will be no more than 1% through 2016. To compensate for reduced revenue, investors are urging manufacturers to cut expenses that do not add value. One such expense, in many investors’ eyes, is research and development (R&D). Read more »

What Is The Value Of Outsourcing?

Stephanie Sutton Pharm Tech EuropeOutsourcing can have its benefits, but how often do we bother to measure the actual value of our outsourcing relationships? Or the innovation that it delivers? In Europe, at least, the answer is: not very often.

This week, Warwick Business School (UK) released a study (sponsored by Cognizant) looking at European C-suite attitudes to outsourcing. The study encompassed 250 CIOs and CFOs across Benelux, France, Germany, Switzerland, the Nordics and the UK. Read more »

Next Page »